The Effect of Alogliptin Combined With Actoplus Met on Glucose and Lipid Metabolism and Pancreatic Function in Patients With T2DM Complicated With MAFLD

Starting soon · Phase 4

Conditions studied: T2DM, MAFLD

In brief

To compare the efficacy and safety of the combination of alogliptin and actoplus met with that of actoplus met alone in improving the glucose and lipid metabolism and pancreatic function in T2DM patients complicated with MAFLD.

Key facts

Study ID

NCT07289750

Run by

The Fourth Affiliated Hospital of Zhejiang University School of Medicine

People needed

80

Starts

2026-05-01

Expected to finish

2027-08-31

Last updated by the study team

2026-03-24

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinical diagnosis of T2DM
• Clinical diagnosis of MAFLD
• HbA1c: 6.5-9.5%
• BMI: 19-35 kg/m2
• No hypoglycemic drugs or insulin have been used within half a year

You may not qualify if…

• Severe infections, surgeries and other emergency
• Other types of diabetes
• Severe cardiovascular, brain, liver and kidney disorders
• Malignant tumor

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.